TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38297229

Group type: EXPERIMENTAL
Intervention: EHR heart health tool for cancer survivors
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Self-reported CVH factors
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: EHR-based categorization of CVH factors
Number of subjects: 502
Study: 38297266

Group type: EXPERIMENTAL
Intervention: Caregiver-administered anthropometric assessments (no-contact protocol)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard assessor-led protocol
Number of subjects: 76
Study: 38297285

Group type: EXPERIMENTAL
Intervention: Infrazygomatic (IZC) miniscrew-anchored Carriere Motion appliance (CMA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Essix retainer-anchored Carriere Motion appliance (CMA)
Number of subjects: 32
Study: 38297308

Group type: EXPERIMENTAL
Intervention: Laser-treated surfaces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Machined surfaces
Number of subjects: 0
Study: 38297337

Group type: EXPERIMENTAL
Intervention: Vi-DT vaccine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vi-PS vaccine (control)
Number of subjects: 200
Study: 38297352

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX) alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX) plus paclitaxel (PAC)
Number of subjects: 23
Study: 38297390

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional bupivacaine (CB)
Number of subjects: 80
Study: 38297397

Group type: EXPERIMENTAL
Intervention: Modified colonoscopy with targeted sampling alone
Number of subjects: 1952

Group type: COMPARATOR
Intervention: Standard of care high-definition white-light colonoscopy with 32 to 40 non-targeted biopsies of non-neoplastic-appearing mucosa along with a sampling of abnormal-appearing mucosa
Number of subjects: 1952
Study: 38297399

Group type: EXPERIMENTAL
Intervention: FINGER 2.0 intervention (lifestyle + metformin if eligible)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Regular health advice (control arm)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day or 1000 mg/day)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 38297524

Group type: COMPARATOR
Intervention: Continue DMARDs at 100% dose
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Taper DMARDs to 50% dose
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Stop DMARDs after tapering to 50% dose for 6 months
Number of subjects: 303
Study: 38297916

Group type: EXPERIMENTAL
Intervention: Exebacase + antibiotics
Number of subjects: 259

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 259
Study: 38298058

Group type: EXPERIMENTAL
Intervention: Tofacitinib (tablet/solution) administered twice daily (b.i.d.)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Tofacitinib (oral solution)
Number of subjects: 246
Study: 38298125

Group type: EXPERIMENTAL
Intervention: mRNA-1345 (50, 100, or 200 µg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA-1345 (100 µg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA-1345 (100 µg, 3 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38298420

Group type: EXPERIMENTAL
Intervention: CD4/CD8-positive selection of CD22 CAR T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD4/CD8-negative selection of CD22 CAR T cells
Number of subjects: 0
Study: 38298510

Group type: EXPERIMENTAL
Intervention: PSMA radioligand therapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: cGAP
Number of subjects: 23
Study: 38298551

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRV-B) intervention for 10 minutes twice daily for 4 weeks using Polar H10 ECG and Elite HRV app
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRV-B) intervention
Number of subjects: 13
Study: 38298861

Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg) administered intravenously at weeks 0, 2, 6, then every 8 weeks for 26 or 52 weeks
Number of subjects: 27
Study: 38299059

Group type: EXPERIMENTAL
Intervention: ATI-1777 topical solution
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 48
Study: 38299306

Group type: EXPERIMENTAL
Intervention: Hydration intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 38
Study: 38299334

Group type: EXPERIMENTAL
Intervention: Transradial access (n=58)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transfemoral access (n=58)
Number of subjects: 120
Study: 38299348

Group type: EXPERIMENTAL
Intervention: Ultrasound-assessed internal jugular vein (JV) distensibility with a threshold of 1.6
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: JV distensibility ratio >1.6
Number of subjects: 201

Group type: COMPARATOR
Intervention: High JV distensibility ratio (>1.6)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Low JV distensibility ratio (≤1.6)
Number of subjects: 201
Study: 38299363

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 698
Study: 38299416

Group type: COMPARATOR
Intervention: 400 IU cholecalciferol + placebo three times daily (Group I)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 600 mg curcumin + 15,800 mg piperine once daily and three times daily placebo (Group II)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 400 IU cholecalciferol three times daily and 600 mg curcumin + 15,800 mg piperine once daily (Group III)
Number of subjects: 45
Study: 38299468

Group type: EXPERIMENTAL
Intervention: Renal stent implantation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Large-sized bare-metal coronary stent (BMCS) implantation
Number of subjects: 63
Study: 38299514

Group type: EXPERIMENTAL
Intervention: 7.5F Mini Flexible Ureteroscope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38299539

Group type: EXPERIMENTAL
Intervention: Camonsertib (RP-3500) at a dose of 160 mg QD given 3 days/week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Camonsertib (RP-3500) in combination with talazoparib, olaparib, niraparib, lunresertib, or gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38299578

Group type: EXPERIMENTAL
Intervention: Isatuximab-pomalidomide-dexamethasone (Isa-Pd)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Pomalidomide-dexamethasone (Pd)
Number of subjects: 307
Study: 38299639

Group type: COMPARATOR
Intervention: Renin-angiotensin system (RAS) inhibition
Number of subjects: 4856

Group type: EXPERIMENTAL
Intervention: Tonsillectomy in addition to standard care
Number of subjects: 4856

Group type: COMPARATOR
Intervention: Anticoagulant therapy, fish oil, and traditional Chinese medicines
Number of subjects: 4856

Group type: COMPARATOR
Intervention: Antimalarial therapy
Number of subjects: 4856
Study: 38299667

Group type: EXPERIMENTAL
Intervention: High CD74 expression
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Anti-CD74 therapy
Number of subjects: 973
Study: 38300235

Group type: EXPERIMENTAL
Intervention: PP6M
Number of subjects: 178

Group type: COMPARATOR
Intervention: PP3M
Number of subjects: 178

Group type: COMPARATOR
Intervention: PP1M
Number of subjects: 178
Study: 38300292

Group type: EXPERIMENTAL
Intervention: Wild blueberry supplementation (single dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wild blueberry supplementation (six weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (six weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Biomarkers (both groups)
Number of subjects: 60
Study: 38300339

Group type: EXPERIMENTAL
Intervention: Whole blood samples from TN patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pain-free controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathway enrichment analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPI network analysis
Number of subjects: 0
Study: 38300341

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus platinum-etoposide chemotherapy (200 mg pembrolizumab every 3 weeks, 75 mg cisplatin)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus platinum-etoposide chemotherapy
Number of subjects: 15
Study: 38300408

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 113

Group type: COMPARATOR
Intervention: Guselkumab 100 mg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg and Guselkumab 100 mg
Number of subjects: 113
Study: 38300710

Group type: EXPERIMENTAL
Intervention: T-DM1 + Pertuzumab (P)
Number of subjects: 129
Study: 38300759

Group type: EXPERIMENTAL
Intervention: Omega-3 Only
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Omega-3 + CBT
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control
Number of subjects: 290

Group type: COMPARATOR
Intervention: CBT Only
Number of subjects: 290
Study: 38300838

Group type: EXPERIMENTAL
Intervention: Chamomile tea (3 g in 150 mL water)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chamomile extract capsule (500 mg)
Number of subjects: 8
Study: 38301149

Group type: EXPERIMENTAL
Intervention: Ponesimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 0
Study: 38301173

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38301187

Group type: EXPERIMENTAL
Intervention: Olaparib (OL)
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 1538
Study: 38301385

Group type: EXPERIMENTAL
Intervention: Revie ⊕ intervention
Number of subjects: 58
Study: 38301418

Group type: EXPERIMENTAL
Intervention: Interdisciplinary rounds for family engagement
Number of subjects: 52
Study: 38301673

Group type: EXPERIMENTAL
Intervention: Covered stents
Number of subjects: 94

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 94
Study: 38301682

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil withdrawal (tapered over 12 weeks)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Mycophenolate mofetil maintenance (1-3g per day for 60 weeks)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil withdrawal
Number of subjects: 102

Group type: COMPARATOR
Intervention: Mycophenolate mofetil maintenance
Number of subjects: 102
Study: 38302093

Group type: EXPERIMENTAL
Intervention: Daily oral iron supplementation (dosage and duration not specified)
Number of subjects: 0
Study: 38302221

Group type: EXPERIMENTAL
Intervention: RVd/R (lenalidomide 25 mg orally on days 1-14; bortezomib 1.3 mg/m2)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: RVd/E-R
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: E-RVd/R
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: E-RVd/E-R
Number of subjects: 564
Study: 38302281

Group type: EXPERIMENTAL
Intervention: Tablet-based car restraint educational intervention using Computer Intervention Authoring Software (CIAS)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Printed handouts on car restraint safety (Control)
Number of subjects: 211
Study: 38302299

Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Patient education brochure
Number of subjects: 72
Study: 38302476

Group type: EXPERIMENTAL
Intervention: Guadecitabine (starting at 60 mg/m²); duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Durvalumab; duration not specified.
Number of subjects: 0
Study: 38302483

Group type: EXPERIMENTAL
Intervention: Extension exercises
Number of subjects: 56

Group type: COMPARATOR
Intervention: Flexion exercises
Number of subjects: 56
Study: 38302715

Group type: EXPERIMENTAL
Intervention: Sugemalimab (1,200 mg) plus chemotherapy (cisplatin 80 mg)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (cisplatin 80 mg)
Number of subjects: 540
Study: 38302718

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 907

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 907
Study: 38302725

Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks (≤35 cycles)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Treatment of physician's choice chemotherapy (TPC)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Lenvatinib+pembrolizumab
Number of subjects: 155
Study: 38302765

Group type: EXPERIMENTAL
Intervention: Zolpidem (open-label trial)
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Daridorexant (phase III trial)
Number of subjects: 1044
Study: 38302850

Group type: EXPERIMENTAL
Intervention: Deep Learning (DL) model for pneumonia diagnosis on chest x-ray (CXR)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Radiologists reviewing CXR
Number of subjects: 430

Group type: COMPARATOR
Intervention: Emergency physicians reviewing CXR
Number of subjects: 430

Group type: COMPARATOR
Intervention: Computed Tomography (CT) for pneumonia diagnosis
Number of subjects: 430
Study: 38302933

Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-1, 4 cycles of 7.4 GBq
Number of subjects: 48
Study: 38302936

Group type: EXPERIMENTAL
Intervention: Baseline characteristics assessment including clinical characteristics, laboratory testing, imaging, Kansas City Cardiomyopathy Questionnaire (KCCQ), Physical Activity Scale of the Elderly (PASE), and cardiopulmonary exercise testing (CPET).
Number of subjects: 691
Study: 38302990

Group type: EXPERIMENTAL
Intervention: MED-amplified dietary pattern (500 kcal/day from eight MED target foods: avocado, basil, cherry, chickpea, oat, red bell pepper, walnut, and alternating protein source of salmon or unprocessed, lean beef)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Habitual/Western dietary pattern (500 kcal/day from six non-MED target foods: cheesecake, chocolate frozen yogurt, refined grain bread, sour cream, white potato, and unprocessed, lean beef)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MED-amplified dietary pattern
Number of subjects: 0

Group type: COMPARATOR
Intervention: Habitual/Western dietary pattern
Number of subjects: 0
Study: 38302995

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: lacto-ovo vegetarian diet (VD)
Number of subjects: 52
Study: 38303009

Group type: EXPERIMENTAL
Intervention: E-bibliotherapy
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 192
Study: 38303019

Group type: EXPERIMENTAL
Intervention: Usual care plus a comprehensive tailored rehabilitation intervention focusing on supporting return to work (RTW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 38303550

Group type: EXPERIMENTAL
Intervention: Transitional care model with month-long nurse-led home visits and long-term heart function clinic visits
Number of subjects: 2494

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2494

Group type: EXPERIMENTAL
Intervention: Transitional care model
Number of subjects: 2494
Study: 38303653

Group type: EXPERIMENTAL
Intervention: High risk of sleep apnea
Number of subjects: 0
Study: 38303926

Group type: EXPERIMENTAL
Intervention: Mediterranean dietary intervention (without personalized meal planning)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: NAFLD patients
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: NAFLD patients with mild steatosis
Number of subjects: 155
Study: 38304039

Group type: EXPERIMENTAL
Intervention: T+N (toripalimab + nab-paclitaxel)
Number of subjects: 531

Group type: COMPARATOR
Intervention: P+N (placebo + nab-paclitaxel)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: T+N (toripalimab + nab-paclitaxel) with 80% reimbursement
Number of subjects: 531

Group type: COMPARATOR
Intervention: P+N (placebo + nab-paclitaxel) with 80% reimbursement
Number of subjects: 531
Study: 38304225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565

Group type: COMPARATOR
Intervention: Phentermine 30 mg
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: PHEN/TPM (15 mg/92 mg)
Number of subjects: 565

Group type: COMPARATOR
Intervention: PHEN/TPM vs Placebo
Number of subjects: 565

Group type: COMPARATOR
Intervention: PHEN/TPM vs Phentermine 30 mg
Number of subjects: 565
Study: 38304227

Group type: EXPERIMENTAL
Intervention: e-HOPE (online caregiver education resource)
Number of subjects: 16
Study: 38304609

Group type: EXPERIMENTAL
Intervention: Faricimab
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Port Delivery System (PDS) with ranibizumab
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: PDS
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Faricimab and PDS
Number of subjects: 5000
Study: 38304733

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified bouillon cubes (upper-level)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified bouillon cubes (lower-level)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bouillon cube fortified with iodine only (control)
Number of subjects: 0
Study: 38304743

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy (sintilimab combined with nab-paclitaxel and carboplatin) for 2-3 cycles prior to surgical resection.
Number of subjects: 30
Study: 38304826

Group type: EXPERIMENTAL
Intervention: Effector (E) GTA002 cells at E:T ratios of 10:1, 3:1, 1:1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flow cytometry panels for NK cell potency assessment
Number of subjects: 0
Study: 38305104

Group type: EXPERIMENTAL
Intervention: High FVIII/PC ratio on postoperative day 2
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: High FVIII/PC ratio
Number of subjects: 51
Study: 38305278

Group type: EXPERIMENTAL
Intervention: Endocuff with AI
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: AI alone
Number of subjects: 682

Group type: COMPARATOR
Intervention: Standard high-definition (HD) colonoscopy
Number of subjects: 682
Study: 38305378

Group type: EXPERIMENTAL
Intervention: Ridinilazole (200 mg twice daily for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin (125 mg 4 times daily for 10 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ridinilazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study: 38305420

Group type: EXPERIMENTAL
Intervention: EDOF intraocular lens (IOL) in the dominant eye
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CT-IOL in the nondominant eye
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combined EDOF/CT-IOL approach
Number of subjects: 37
Study: 38305478

Group type: EXPERIMENTAL
Intervention: Intracanalicular dexamethasone 0.4 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical prednisolone acetate (PA) 1%
Number of subjects: 30
Study: 38305707

Group type: EXPERIMENTAL
Intervention: ITGA (Intubated General Anesthesia)
Number of subjects: 61

Group type: COMPARATOR
Intervention: NMB (Neuromuscular Blocking)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: NB (Superior Laryngeal Nerve Block)
Number of subjects: 61
Study: 38305868

Group type: EXPERIMENTAL
Intervention: Giredestrant
Number of subjects: 179
Study: 38306042

Group type: EXPERIMENTAL
Intervention: Standard BP treatment
Number of subjects: 457

Group type: COMPARATOR
Intervention: Intensive BP treatment
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Mean BP
Number of subjects: 457
Study: 38306312

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 38306343

Group type: EXPERIMENTAL
Intervention: HIIE (8x4 min cycling bouts at 85% of VO2peak)
Number of subjects: 8

Group type: COMPARATOR
Intervention: CON (matched kJ production from HIIE at 50% of VO2peak)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HIIE
Number of subjects: 8
Study: 38306389

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study: 38306602

Group type: EXPERIMENTAL
Intervention: MLLT10 fusions (n=127)
Number of subjects: 2080

Group type: EXPERIMENTAL
Intervention: KMT2A::MLLT10 (n=104)
Number of subjects: 2080

Group type: EXPERIMENTAL
Intervention: PICALM::MLLT10 (n=13)
Number of subjects: 2080
Study: 38306745

Group type: EXPERIMENTAL
Intervention: Delandistrogene moxeparvovec gene therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids (additional administration starting one day preinfusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring liver function, troponin-I levels, and platelet counts postinfusion
Number of subjects: 0
Study: 38306883

Group type: EXPERIMENTAL
Intervention: 60 mL/day EVOO
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (usual diet and no supplemental EVOO)
Number of subjects: 52
Study: 38306892

Group type: EXPERIMENTAL
Intervention: Mycoprotein-containing food products (MYC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Meat/fish control products (CON)
Number of subjects: 72
Study: 38306953

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38307098

Group type: EXPERIMENTAL
Intervention: 927 mg subcutaneous lenacapavir plus 30 mg/kg intravenous teropavimab and 10 mg/kg intravenous zinlirvimab
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 927 mg subcutaneous lenacapavir plus 30 mg/kg intravenous teropavimab and 30 mg/kg intravenous zinlirvimab
Number of subjects: 21
Study: 38307365

Group type: EXPERIMENTAL
Intervention: Ablation (NA group)
Number of subjects: 2204

Group type: COMPARATOR
Intervention: Drug therapy (NA group)
Number of subjects: 2204

Group type: EXPERIMENTAL
Intervention: Ablation (non-NA group)
Number of subjects: 2204

Group type: COMPARATOR
Intervention: Drug therapy (non-NA group)
Number of subjects: 2204
Study: 38307421

Group type: EXPERIMENTAL
Intervention: hsCRP ≥2 mg/L
Number of subjects: 232

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 232

Group type: COMPARATOR
Intervention: hsCRP <2 mg/L
Number of subjects: 232
Study: 38307528

Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low PEEP/FiO2 table-guided PEEP
Number of subjects: 0
Study: 38307529

Group type: EXPERIMENTAL
Intervention: NEWS-1 care (triggered by a high NEWS-2 score ≥5)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (initial period before switching to NEWS-1 care)
Number of subjects: 200